 Kinnate Biopharma Inc NASDAQ: KNTE, which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised 276 million in gross proceeds in an initial public offering priced at 20 per share. The Kinnate Biopharma Analyst: Following the end of the IPO quiet period, SVB Leerink analyst Andrew Berens initiated coverage of Kinnate Biopharma with an Outperform rating and 52 price target. 